Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long … According to collaboration terms, Atara will receive an upfront payment of $60 million from Bayer for the development of … $12.89 $14.99. Atara Biotherapeutics Inc (NASDAQ:ATRA) has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel … Jeannie M. Fontana is Executive Director of Patient Advocacy at Sanford Burnham Prebys Medical Discovery Institute. The company’s stock price has collected -4.39% of loss in the last five trading sessions. The sale was disclosed in a legal filing with the SEC, which can be … Claim your 1-week free trial to StreetInsider Premium here. Get the latest news and real-time alerts from Atara Biotherapeutics, Inc. (ATRA) stock at Seeking Alpha. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today … So far 564,200 shares have traded compared to average … Stockhouse.com use cookies on this site. By continuing to use our service, you agree to our use of cookies. SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent business … Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit. Get Atara Biotherapeutics Inc (ATRA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Amarin and Atara Biotherapeutics could both be diamonds in the rough. ATRA earnings call for the period ending December 31, 2019. These two cancer stocks are trading at a pittance compared to their long-term value propositions. ATRA earnings call for the period ending September 30, 2019. Atara's shares have collapsed this year. Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider Xiaoli Wang. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. While that cash runway isn't too concerning, … Its experimental compound tabelecleucel (tab-cel) is being investigated in two cancers, Epstein-Barr virus (EBV) associated post-transplant … Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Get today's Atara Biotherapeutics Inc stock news. Fill out general application, and we will find a right position for you, or notify you when a right one becomes available. Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease. Find the latest news headlines from Atara Biotherapeutics, Inc. Common Stock (ATRA) at Nasdaq.com. Share . Atara Biotherapeutics is a publicly traded clinical-stage biotechnology company with over 300 employees with a passion for advancing medical care. Atara Biotherapeutics Inc (ATRA) Q4 2020 Earnings Call Transcript. 06:48 AM … Atara Biotherapeutics presents long-term OS data from Phase 2 Tab-cel studies 02/08/21 Atara Biotherapeutics to present tabelecleucel data at ASTCT meeting 01/04/21 Atara Biotherapeutics provides update on BLA submission for tab-cel 12/07/20 Atara presents evaluation of CAR T Cell Therapy ATA3219 at … Atara Biotherapeutics To Participate At The Cowen Virtual Oncology Innovation Summit. The company report on January 11, 2021 that Atara Biotherapeutics Will Present Recent Advancements and Key … Tuesday, June 30, 2020. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative … Atara Biotherapeutics will be financed initially by KPCB, and Isaac Ciechanover, M.D., a former partner at KPCB, will serve as the president and chief executive officer. Don’t see your interest? Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Pharmaceutical, Biotech, Medical & Healthcare Network: Business, Jobs, Events & News. Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider Therefore, from June 2020 it had roughly 17 months of cash runway. Do the numbers hold clues to what lies ahead for the stock? Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease. Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Press Release reported on 04/27/21 that Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 The Fly team scours all sources of company news, from mainstream to cutting edge,then filters out the noise to deliver shortform stories consisting of only market moving content. Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara Biotherapeutics, Inc. (ATRA) Company Bio. Stable Share Price: ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- … 03/02 09:30. During the last session, Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s traded shares were 688,277, with the beta value of the company hitting 2.37. We cover the latest Atara Biotherapeutics Inc headlines and breaking news impacting Atara Biotherapeutics Inc stock performance. Volume352,631 shs. $13.15 $13.56. Atara Biotherapeutics Inc (ATRA) Q4 2020 Earnings Call Transcript. Atara Biotherapeutics Inc. [NASDAQ: ATRA] traded at a low on 01/15/21, posting a -1.27 loss after which it closed the day’ session at $18.61. Atara Biotherapeutics Stock News NASDAQ:ATRA. MT Newswires. Atara Biotherapeutics (Atara Biotherapeutics: ATRA) stock research, analysis, profile, news, analyst ratings, key … Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients … Atara Biotherapeutics, Inc. (ATRA) (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Atara Biotherapeutics upgraded to overweight from neutral at J.P. Morgan MarketWatch. May 13, 2021 4:01 PM EDT. Since then, ATRA shares have increased by 44.7% and is now trading at $14.41. Atara Biotherapeutics news and ATRA price. 06:46 AM ET. Amgen will have a minority equity interest in Atara Biotherapeutics. About DelveInsight. Atara Biotherapeutics news and ATRA price. Average Volume902,427 shs. With our lead program in Phase 3 clinical development, Atara … The Short-Term Technical score evaluates a stock's trading pattern over the past month and is most useful to short-term stock and option traders. Volume today is light. Atara Biotherapeutics Inc ... And as we've described, we have achieved the enrollment to activate the interim analysis, which is great news. Atara Biotherapeutics Inc. (NASDAQ: ATRA) is finding itself caught between a rock and a hard place after Friday’s drug study news. Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. Press Release reported on 04/02/21 that Atara Biotherapeutics … Cell Based Assays ... Senior Scientist at Atara Biotherapeutics. Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel ® Studies for Epstein-Barr Virus … Atara Biotherapeutics News Headlines $13.18-0.15 (-1.13 %) (As of 06/4/2021 12:00 AM ET) Add. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases. Atara Biotherapeutics has such a small amount of debt that we'll set it aside, and focus on the US$348m in cash it held at June 2020. It supports Pharma companies by providing comprehensive end-to-end … The company was founded in 2012 and is based in South San Francisco, California. The stock has traded between $14.17 and $15.35 so far today. Atara Biotherapeutics Inc. (ATRA) estimates and forecasts. Atara Biotherapeutics Inc. [NASDAQ: ATRA] traded at a low on 01/15/21, posting a -1.27 loss after which it closed the day’ session at $18.61. May 13, 2021 4:01pm EDT. Share Price & News. The company’s stock price has collected 5.13% of gains in the last five trading sessions. Importantly, its cash burn was US$242m over the trailing twelve months. Analysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte, and others. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results … 07:19 AM ET. Latest Share Price and Events. MT Newswires. To initiate the BLA, Atara is awaiting a procedural decision from the FDA related to how the historical non-pivotal data should be presented in the BLA submission. Atara Biotherapeutics started at outperform at Evercore ISI MarketWatch. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 5,820 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, June 8th. Atara Biotherapeutics, Inc. (ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Atara s … Atara Biotherapeutics’ Cancer Drug Might—Might!—Have Applications for MS. Bay Area company Atara Biotherapeutics is focused on immuno-oncology. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress Yahoo News Singapore 2 days ago Atara Biotherapeutics Reports Q1 Loss Per Share of $0.86 Breaking News: ALVR latest news. --Analyst Actions: Citigroup Upgrades Atara Biotherapeutics to Buy From Neutral; Price Target is $27. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel … View the latest Atara Biotherapeutics Inc. (ATRA) stock price, news, historical charts, analyst ratings and financial information from WSJ. The stock was sold at an average price of $14.06, for a total transaction of $81,829.20. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic … DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Atara Biotherapeutics Inc. (NASDAQ:ATRA) went down by -2.12% from its latest closing price compared to the recent 1-year high of $28.20. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. $8.90 $28.20.

Country Turkey In German, Rice Regular Decision 2025, Portnahaven Property For Sale, Why Did Chrissy Teigen Harass Courtney, Petrochemicals Products, Hanging Shower Soap Holder, Our State Magazine October 2020,